Wall Street is positive on Burning Rock Biotech Ltd (BNR). On average, analysts give the stock a Strong Buy rating. The average price target is $29.55, which means analysts expect the stock to increase by 172.85% over the next twelve months. That average ranking earns the stock an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating BNR a Strong Buy today. Find out what this means to you and get the rest of the rankings on BNR!